Compare Adaptive Biotechnologies Corp (ADPT) vs Freeport-McMoRan Inc (FCX) Price & Performance

ADPT trades at $24.46, down 3.66% today but remains near its 52-week high. The stock shows bullish technical signals with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025, while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to a pure-play MRD diagnostics business following the Immune Medicine separation has generated positive investor sentiment, with 65% of analysts maintaining buy ratings.

Outlook remains cautiously optimistic as ADPT's MRD business demonstrates strong growth potential with 49% YoY revenue expansion. Key risks include persistent negative profitability metrics and execution challenges during the business separation. The consensus price target of $25.50 suggests modest upside potential from current levels, contingent on continued operational improvement.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.